Doxy-PEP Research Roundup for STI Awareness Week
Office of Infectious Disease and HIV/AIDS Policy
Working toward a world free of infectious disease.
During this week’s observance of Sexually Transmitted Infections (STI) Awareness Week, HIV.gov is sharing a roundup of some of our recent coverage about the use of Doxy-PEP to prevent bacterial STIs. Doxy-PEP refers to the use of the oral antibiotic doxycycline as post-exposure prophylaxis after condomless sex. Research on the efficacy and effectiveness of this new STI prevention tool has been presented at several recent conferences where HIV.gov spoke to national experts about it.
The Latest Doxy-PEP Research Findings
Most recently, we spoke with NIH’s Dr. Carl Dieffenbach and CDC’s Dr. Jonathan Mermin about the accumulating real-world evidence of the effectiveness of Doxy-PEP presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI).
Dr. Dieffenbach, Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, discussed two studies. First was a study by the San Francisco Department of Public Health (SFDPH) on implementation of Doxy-PEP in a single clinic which offered Doxy-PEP to all clients using HIV PrEP and saw bacterial STIs decrease among those who used Doxy-PEP by nearly 60% in less than a year, with the highest declines for syphilis (78%) and chlamydia (67%). Then he highlighted a SFDPH presentation of the first findings to measure the effect of Doxy-PEP at the population level, showing a substantial and sustained decline in the number of chlamydia and early syphilis infections in the city among men who have sex with men and transgender women over the 13 months after the Department released its guidelines for the use of Doxy-PEP.
In another interview at CROI 2024, Dr. Mermin, Director of the CDC’s National Center for HIV, Viral Hepatitis, STD, and TB Prevention, characterized Doxy-PEP as “the most exciting intervention for STI prevention in two decades.” However, he also observed that there remains a concerning evidence gap on the effectiveness of Doxy-PEP among cisgender women. View our conversation with Dr. Mermin.
Just ahead of the start of CROI, NIAID Director Dr. Jeanne Marrazzo underscored the importance of considering gender-specific factors in the design of biomedical prevention studies. Read Biomedical STI Prevention Evidence Is Inadequate for Cisgender Women.
领英推荐
Earlier Conversations about Doxy-PEP
We previously spoke to Dr. Dieffenbach about Doxy-PEP at the International AIDS Conference in Montreal in 2022, after Annie Luetkemeyer, MD, professor of infectious diseases at Zuckerberg San Francisco General Hospital at UCSF, presented findings from the first Doxy-PEP study, which she co-led. That study found that the use of Doxy-PEP by sexually active men who have sex with men diagnosed with HIV or taking or planning to take HIV PrEP medication prevented the acquisition of STIs when the Doxy-PEP was taken within 72 hours of having condomless sex.
Seven months later, at CROI 2023, we spoke with Dr. Dieffenbach and Dr. Mermin about additional data from that first Doxy-PEP study; results from a second study from France that confirmed the results of the original study regarding reductions in chlamydia, gonorrhea, and syphilis; and results from a study among cisgender women using PrEP in Kenya that indicated that Doxy-PEP may not be effective for women.
In October 2023, CDC issued draft guidelines on the use of Doxy-PEP and invited public comment. CDC anticipates publishing the final Doxy-PEP guidance later this year.